The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

96 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-31

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To evaluate expression levels of circANKRD36 in the development and progression of DN.
2. To investigate correlation between expression levels of circANKRD36 and stages of DN.
3. To investigate correlation between expression levels of circANKRD36 and pro-inflammatory cytokine (TNF-α and IL-6) in T2DM patients with CKD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preliminary Study of CXCL3 As a Biomarker of Diabetic Kidney Disease

NCT06639529

Diabetic Kidney Disease (DKD)

COMPLETED NA

Evaluating The Roles of Novel Inflammatory Markers Compared to MCP-1 in Type 2 Diabetic Nephropathy

NCT07173686

Diabetic Nephropathy

NOT_YET_RECRUITING

Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD

NCT06069076

Diabetic Kidney Disease

NOT_YET_RECRUITING

Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics

NCT05378282

Type 2 Diabetes Type 2 Diabetes With Renal Manifestations

COMPLETED

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

NCT05687890

Diabetic Kidney Disease IgA Nephropathy

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders that's become a global health burden affecting 463 million people worldwide according to the International Diabetes Federation (IDF). Diabetic nephropathy(DN) is one of the most common secondary complications of DM and is becoming a major cause of morbidity and mortality among diabetic patients . DN is a microvascular complication occurring in approximately 20-40% of patients with T2DM . DN has been described as a glomerular disorder with the following phases: glomerular hyperfiltration, incipient nephropathy, microalbuminuria, overt proteinuria and end-stage renal disorder. Microalbuminuria is the gold standard for the early diagnosis of DN. However, many studies have suggested that it is inadequate and has some drawbacks. Recent novel biomarkers have been accepted for early diagnosis and progression of DN in patients with T2DM . Renal cells are capable of synthesizing pro-inflammatory cytokines such as tumor necrotic factor-alpha (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6), these cytokines acting in a paracrine or autocrine manner that leading to the development and progression of several renal disorders .Circular RNAs are class of endogenous non coding RNAs and are associated with numerous diseases like T2DM. Circular ankyrin repeat domain 36 (circANKRD36) involved in T2DM and inflammation-associated pathways via interaction with miRNAs, including hsa-miR-3614-3p, hsa-miR-498, and hsa-miR-501-5p. The expression of circANKRD36 was upregulated in peripheral blood leucocytes and was correlated with chronic inflammation in T2DM. Therefore, circANKRD36 can be used as a potential biomarker for screening chronic inflammation in patients with T2DM.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group1:

28 control

circANKRD36 as a new biomarker

Intervention Type GENETIC

expression levels of circANKRD36 in the development and progression of DN

Group 2:

68 T2DM patients

circANKRD36 as a new biomarker

Intervention Type GENETIC

expression levels of circANKRD36 in the development and progression of DN

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

circANKRD36 as a new biomarker

expression levels of circANKRD36 in the development and progression of DN

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed as Type 2 Diabetes Mellitus

Exclusion Criteria

* Any other clinically systemic acute or chronic inflammation disease/s.
* Autoimmune disease.
* Any endocrine disease other than T2DM.
* Cancer.
* Chronic hepatic or renal failure.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes